Medicine & Life Sciences
Safety-net Providers
100%
Drug Therapy
81%
Bevacizumab
73%
Breast Neoplasms
64%
rasburicase
57%
Jehovah's Witnesses
51%
Colonic Neoplasms
45%
Kinesin
42%
Triple Negative Breast Neoplasms
39%
Induction Chemotherapy
39%
gemcitabine
39%
Chemoradiotherapy
35%
Colorectal Neoplasms
35%
Platinum
34%
Rectal Neoplasms
33%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32%
Meals
29%
Hypertension
29%
Albumins
28%
Lymphoma
27%
Costs and Cost Analysis
27%
Weight Loss
27%
Income
27%
Intercellular Signaling Peptides and Proteins
26%
Neutrophils
25%
Blood Platelets
25%
Outpatients
24%
Hospitalization
24%
Radiotherapy
22%
Phosphorylation
22%
Therapeutics
22%
Mutation
21%
Monoclonal Antibodies
20%
Blood Transfusion
20%
Recurrence
20%
Cytotoxins
19%
romiplostim
18%
Darbepoetin alfa
17%
B-Lymphocytes
17%
Incidence
16%
Philadelphia Chromosome
14%
Fluorouracil
13%
Leucovorin
13%
Progression-Free Survival
12%
Platinum Compounds
12%
Quality Improvement
11%
Residual Neoplasm
11%
Tumor Lysis Syndrome
11%
Taxoids
10%
Lymphoma, Large B-Cell, Diffuse
10%
Social Sciences
costs
37%
hospitalization
36%
medication
22%
savings
20%
act
19%
time
11%
physician
10%
hospital system
9%
methodology
9%
laboratory testing
9%
drug
8%
electronics
8%
Medical records
7%
pharmacist
7%
communication
5%
indication
5%
finance
5%
health
5%
nurse
5%